GlassScriptPhysician profile
Alice Grasso Mccaslin
NPI 1508346115
$4,384.75
in general payments reported to CMS, 2019-2025
21 companies · $474 in 2025
The $474 reported for 2025 was more than what 76% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $302 · 2020: $250 · 2021: $694 · 2022: $1,021 · 2023: $1,010 · 2024: $634 · 2025: $474.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,020 · Education: $97.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,020.04 |
| Education | $97.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $903.23 | 2019-2025 | Total30, Precision7, Dailies Total1 |
| Johnson & Johnson Vision Care, INC. | $617.61 | 2020-2025 | Acuvue |
| Mallinckrodt Hospital Products INC. | $577.72 | 2021-2025 | Acthar |
| Sun Pharmaceutical Industries INC. | $283.59 | 2019-2025 | Cequa |
| Lkc Technologies, INC. | $271.80 | 2024-2025 | |
| Oyster Point Pharma, INC. | $215.51 | 2022-2024 | Tyrvaya |
| Kala Pharmaceuticals, INC. | $209.11 | 2021-2022 | |
| Allergan, INC. | $175.52 | 2020-2022 | |
| Biotissue Holdings INC. | $166.77 | 2021-2024 | |
| Tarsus Pharmaceuticals, INC. | $153.77 | 2024-2025 | Xdemvy |
| Coopervision INC. | $143.99 | 2020-2023 | Misight Contact Lens |
| Dompe US, INC. | $125.30 | 2024 | Oxervate |
| Aerie Pharmaceuticals, INC. | $124.74 | 2021 | |
| Horizon Therapeutics Plc | $115.20 | 2023 | Tepezza |
| Abbvie INC. | $82.64 | 2022-2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $51.99 | 2020-2021 | |
| Bausch & Lomb Americas INC. | $51.47 | 2022-2024 | Lotemax Sm, Vyzulta, Xiidra |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $45.38 | 2021 | |
| Carl Zeiss Meditec, INC. | $33.00 | 2022 | |
| Genzyme Corporation | $20.75 | 2022 | |
| Amgen INC. | $15.66 | 2024 | Tepezza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alice Mccaslin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.